 Unity Biotechnology Inc NASDAQ: UBX announced 12-week data from its ongoing Phase 1 safety study of UBX1325 in diabetic macular edema DME and wet age-related macular degeneration AMD, for whom anti-VEGF therapy was no longer considered beneficial. The data show strong and sustained responses following a single injection of UBX1325. 